ARWR Stock: Goldman Sachs Resumes Coverage With $74 Target As Clinical Catalysts Near
Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop. Goldman Analyst Andrea Newkirk highlighted acquisition activity and positive clinical catalysts as key supports for biotech’s recent performance. Earlier this month, Citi kept a Buy rating and $108 price target on Arrowhead, while … Read more